The S&P/ASX 200 is set to bounce strongly thanks to cooler-than-expected US inflation data. Here are today's top stories.
Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare ...
Fintel on MSN
Stifel maintains ResMed (RMD) hold recommendation
Fintel reports that on December 18, 2025, Stifel maintained coverage of ResMed (NYSE:RMD) with a Hold recommendation. Analyst ...
Quality is perhaps one of the most backward looking investment factors, given that it fixates on trailing margins and past ...
Jefferies raised GE Vernova Inc (NYSE: GEV) price target from $736 to $815. Jefferies analyst Julien Dumoulin-Smith upgraded ...
TipRanks on MSN
ResMed price target lowered to $260 from $270 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on ResMed (RMD) to $260 from $270 and keeps a Hold rating on the shares. The stock’s ...
ResMed (RMD) has quietly drifted lower over the past week, but the stock is still up this year, which raises a straightforward question for investors: is this dip an opportunity or a warning? See our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback